← Back to Search

Other

TL-925 for Allergic Conjunctivitis

Phase 2
Recruiting
Research Sponsored by Telios Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals aged 18 years or older
Be older than 18 years old
Must not have
Any ongoing ocular infection (bacterial, viral or fungal)
Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 5 and 7 minutes after cac

Summary

This trial will test a new eye drop called TL-925 for treating allergic conjunctivitis. About 66 participants will be randomly assigned to receive either TL-925 or a placebo. The study

Who is the study for?
This trial is for individuals with allergic conjunctivitis, commonly known as pink eye. Participants should have a history of allergies affecting their eyes and must pass an allergen challenge test. The study excludes those who've recently used certain medications or treatments that could affect the results.
What is being tested?
The trial is testing TL-925, a new treatment for allergic conjunctivitis. It's compared to a placebo (a substance with no active drug). Both are given as eye drops in a double-masked setup, meaning neither participants nor researchers know who receives the real treatment.
What are the potential side effects?
While specific side effects of TL-925 aren't listed here, common side effects from eye drop medications may include temporary discomfort, redness or itching in the eyes, watery eyes, and possible blurred vision.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any current eye infections.
Select...
I don't have any health conditions causing eye redness or discomfort.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 5 and 7 minutes after cac
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 5 and 7 minutes after cac for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Conjunctival Redness
Ocular Itching

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TL-925 ArmActive Control1 Intervention
Subjects will be dosed in clinic.
Group II: Placebo ArmPlacebo Group1 Intervention
Subjects will be dosed in clinic.

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor
10 Previous Clinical Trials
1,599 Total Patients Enrolled
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top